From Casetext: Smarter Legal Research

In re Lorazepam Clorazepate Antitrust Litigation

United States District Court, D. Columbia
Oct 8, 2003
MDL 1290 (TFH), Misc. No. 99ms276, No. 3:03-626 (S.D. Miss.) (D.D.C. Oct. 8, 2003)

Opinion

MDL 1290 (TFH), Misc. No. 99ms276, No. 3:03-626 (S.D. Miss.)

October 8, 2003

Patrick McMurtray, FRAZER DAVIDSON, PA, Jackson, MS, for Plaintiffs.

Mitchell E. Zamoff, HOGAN HARTSON L.L.P., Washington, D.C., for Defendants.

T. Roe Frazer, II, Esq., Patrick McMurtray, Esq., Frazer Davidson, PA, Jackson, MS, for Plaintiffs.

W. Wayne Drinkwater, Jr., Gory T. Wilson, Bradley Arant Rose White, L.L.P., Jackson, Mississippi, for Defendants.

Christopher K. Tahbaz, Debevoise Plimpton, New York, N.Y., for Defendant Cambrex Corporation

David Hickerson, Well, Gotshal Manges, Washington, D.C, for Defendant Gyma Laboratories of America, Inc.

Sidney S. Rosdeitcher, Robert N. Kravitz, Paul, Weiss, Rifkind, Wharton Garrison LLP, New York, N.Y., for Defendant SST Corporation.


STIPULATION AND PROPOSED ORDER


Plaintiffs and defendants, through counsel, hereby agree and stipulate as follows with respect to the briefing of various motions that have been filed in the this action:

1. On or about July 30, 2003, this action was transferred, without objection, to this Court by the JPML.

2. Counsel for plaintiffs has been advised by the Clerk of Court for the United States District Court for the Southern District of Mississippi that the case file has now been sent to this Court.

3. There are two motions pending in this action at this time — (a) Defendants' Motion for Judgment on the Pleadings; and (b) Plaintiffs' Motion to Remand (collectively, the "Motions"). Neither motion has been fully briefed as a result of the stay entered by Judge Wingate prior to the transfer of this action to this Court.

4. The following memoranda need to be filed in order to complete the briefing on the Motions: (a) defendants' reply in support of the motion for judgment on the pleadings; (b) defendants' opposition to plaintiffs' motion to remand; and (c) plaintiffs' reply in support of the motion to remand. Plaintiffs also wish to make a supplemental filing in opposition to the motion for judgment on the pleadings. While defendants reserve all rights to dispute the contents of that supplemental filing, they do not object to the submission of the filing according to the schedule proposed below.

5. Last month, at the parties' request, the Court set a briefing schedule on the Motions under which briefing would conclude in mid-October.

6. Based on the parties' subsequent determination that it would be beneficial to have additional time to brief the Motions and to address certain other issues relating to this action, the parties respectfully propose that the briefing schedule for the Motions be extended by approximately 30 days as follows:

Defendants' Motion for Judgment on the Pleadings

Deadline for plaintiffs' supplemental filing: October 31, 2003

Deadline for defendants' reply: November 19, 2003

Plaintiffs' Motion to Remand

Deadline for defendants' opposition: October 31, 2003

Deadline for plaintiffs' reply: November 19, 2003

SO ORDERED:


Summaries of

In re Lorazepam Clorazepate Antitrust Litigation

United States District Court, D. Columbia
Oct 8, 2003
MDL 1290 (TFH), Misc. No. 99ms276, No. 3:03-626 (S.D. Miss.) (D.D.C. Oct. 8, 2003)
Case details for

In re Lorazepam Clorazepate Antitrust Litigation

Case Details

Full title:IN RE LORAZEPAM CLORAZEPATE ANTITRUST LITIGATION; This document relates…

Court:United States District Court, D. Columbia

Date published: Oct 8, 2003

Citations

MDL 1290 (TFH), Misc. No. 99ms276, No. 3:03-626 (S.D. Miss.) (D.D.C. Oct. 8, 2003)